Palivizumab: a Review of Its Use in the Protection of High Risk Infants Against Respiratory Syncytial Virus (RSV)

Overview

Journal Biologics

Date 2009 Aug 27

PMID 19707346

Citations 17

Authors

Joseph M Geskey

Neal J Thomas

Gretchen L Brummel

Affiliations

Soon will be listed here.

Abstract

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in children less than 1 year of age and causes substantial morbidity. Although there is not currently a vaccine available to prevent RSV infection, prophylaxis with the humanized monoclonal antibody palivizumab has been shown to reduce the rate of RSV hospitalization in premature infants and those infants with chronic lung disease or congenital heart disease. Because palivizumab has not been shown to have a beneficial clinical effect on established RSV disease such as reducing the rate of mechanical ventilation and mortality in children afflicted with RSV, there has been considerable debate as to the cost-benefit ratio of administering palivizumab according to international guidelines. Palivizumab has demonstrated a favorable side-effect profile in clinical trials without the development of anti-palivizumab antibodies. Future studies are needed to determine whether palivizumab, or other more potent monoclonal antibodies which are currently undergoing clinical trials, will reduce the long-term sequelae of RSV infection such as the development of wheezing and asthma.

Citing Articles

Development of an Antiviral Ion-Activated In Situ Gel Containing 18β-Glycyrrhetinic Acid: A Promising Alternative against Respiratory Syncytial Virus.

Ozkan B, Altuntas E, Unlu U, Dogan H, Ozsoy Y, Cakir Koc R Pharmaceutics. 2023; 15(8).

PMID: 37631269 PMC: 10458153. DOI: 10.3390/pharmaceutics15082055.

Development and biophysical characterization of a humanized FSH-blocking monoclonal antibody therapeutic formulated at an ultra-high concentration.

Rojekar S, Pallapati A, Gimenez-Roig J, Korkmaz F, Sultana F, Sant D Elife. 2023; 12.

PMID: 37334968 PMC: 10325703. DOI: 10.7554/eLife.88898.

Development and Biophysical Characterization of a Humanized FSH-Blocking Monoclonal Antibody Therapeutic Formulated at an Ultra-High Concentration.

Rojekar S, Pallapati A, Gimenez-Roig J, Korkmaz F, Sultana F, Sant D bioRxiv. 2023; .

PMID: 37214886 PMC: 10197643. DOI: 10.1101/2023.05.11.540323.

Impact of breastfeeding on the incidence and severity of respiratory syncytial virus (RSV)-associated acute lower respiratory infections in infants: a systematic review highlighting the global relevance of primary prevention.

Mineva G, Purtill H, Dunne C, Philip R BMJ Glob Health. 2023; 8(2).

PMID: 36746518 PMC: 9906265. DOI: 10.1136/bmjgh-2022-009693.

US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives.

Wang S, Yan Y, Ho K Antib Ther. 2021; 4(4):262-272.

PMID: 34909579 PMC: 8664682. DOI: 10.1093/abt/tbab027.

References

Groothuis J . Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group. Pediatr Infect Dis J. 2001; 20(6):628-30. DOI: 10.1097/00006454-200106000-00018. View

Malley R, DeVincenzo J, Ramilo O, Dennehy P, Meissner H, Gruber W . Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998; 178(6):1555-61. DOI: 10.1086/314523. View

Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T . Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003; 35(6):484-9. DOI: 10.1002/ppul.10288. View

Arnold S, Wang E, Law B, Boucher F, Stephens D, Robinson J . Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J. 1999; 18(10):866-9. DOI: 10.1097/00006454-199910000-00006. View

DeVincenzo J . Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res. 2004; 56(6):914-7. DOI: 10.1203/01.PDR.0000145255.86117.6A. View

. Management of infections caused by respiratory syncytial virus. Scand J Infect Dis. 2001; 33(5):323-8. DOI: 10.1080/003655401750173869. View

Korppi M, Piippo-Savolainen E, Korhonen K, Remes S . Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004; 38(2):155-60. DOI: 10.1002/ppul.20058. View

Sorrentino M, Powers T . Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J. 2000; 19(11):1068-71. DOI: 10.1097/00006454-200011000-00007. View

Henderson J, Hilliard T, Sherriff A, Stalker D, Al Shammari N, Thomas H . Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005; 16(5):386-92. DOI: 10.1111/j.1399-3038.2005.00298.x. View

10.

Leclair J, Freeman J, Sullivan B, Crowley C, Goldmann D . Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med. 1987; 317(6):329-34. DOI: 10.1056/NEJM198708063170601. View

11.

Holman R, Curns A, Cheek J, Bresee J, Singleton R, Carver K . Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics. 2004; 114(4):e437-44. DOI: 10.1542/peds.2004-0049. View

12.

Boeckh M, Berrey M, Bowden R, Crawford S, Balsley J, Corey L . Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001; 184(3):350-4. DOI: 10.1086/322043. View

13.

Boyce T, Mellen B, Mitchel Jr E, Wright P, Griffin M . Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000; 137(6):865-70. DOI: 10.1067/mpd.2000.110531. View

14.

Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon J . Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 2005; 23(12):1081-5. View

15.

Zhao X, Chen F, Sullender W . Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology. 2004; 318(2):608-12. DOI: 10.1016/j.virol.2003.10.018. View

16.

. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003; 112(6 Pt 1):1442-6. View

17.

Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon J . Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol. 2007; 42(3):189-92. DOI: 10.1002/ppul.20503. View

18.

Kusuda S, Koizumi T, Sakai T, Fujimura M, Nishida H, Togari H . Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003. Pediatr Int. 2006; 48(4):362-8. DOI: 10.1111/j.1442-200X.2006.02222.x. View

19.

DeVincenzo J, Aitken J, Harrison L . Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. J Pediatr. 2003; 143(1):123-6. DOI: 10.1016/S0022-3476(03)00213-0. View

20.

Stevens T, Sinkin R, Hall C, Maniscalco W, McConnochie K . Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000; 154(1):55-61. View